Software Improvement Group Recognized as a Leader in Gartner® Magic Quadrant™ for Technical Debt Management Tools

27.5.2026 12:06:00 CEST | Business Wire | Press Release

Software Improvement Group (SIG), the global software consultancy behind the Sigrid® software portfolio governance platform, today announced it has been recognized as a Leader in the 2026 Gartner Magic Quadrant™ for Technical Debt Management Tools.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526960241/en/

This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available upon request from SOFTWARE IMPROVEMENT GROUP BV

The Gartner report highlights the growing importance of technical debt management as organizations accelerate software delivery through AI coding assistants and agentic AI. “We believe this Gartner recognition reflects a major shift in software engineering,” said Luc Brandts, CEO of Software Improvement Group. “Technical debt management has evolved from a niche engineering concern into a strategic business priority. As AI accelerates software creation, organizations need visibility into architectural drift, maintainability, security risks, and long-term software sustainability more than ever before.”

The Gartner Magic Quadrant for Technical Debt Management Tools notes that the technical debt management market reflects a consolidation of technologies across static and dynamic analysis, software composition, architecture observability to streamline the remediation process. While AI code assistants are increasingly eﬀective at remediating code-level debt, the market is shifting toward managing architectural technical debt — debt that cuts across multiple systems or architecture layers, which is expected to account for 80% of all technical debt by 2027. We believe what makes Software Improvement Group unique in this market is that architectural debt governance is designed in from the start, not patched in later.

Architectural debt is distinct from code-level issues. It manifests in the relationships between systems: how components are linked, how teams depend on each other's work, and whether the software structure still aligns with its original design intent. AI coding tools compound this problem; they operate within a bounded context window, lack domain knowledge of the broader system, and can fill architectural gaps independently.

With 25 years of experience analyzing billions of lines of code, we feel that portfolio-wide visibility is the only reliable way to detect, prioritize, and govern architectural debt before it destabilizes the systems your business depends on. Learn more about SIG's technical debt management approach.

That same principle extends to how AI-generated code enters your portfolio. Productivity gains from AI coding assistants are real, but so are the risks around quality, security, and legal exposure when that code is deployed without oversight. SIG's AI code governance capability gives organizations the visibility and guardrails to move faster without losing control. “AI coding assistants can improve developer productivity and reduce certain forms of code-level debt, but they also increase the risk of architectural technical debt accumulating at scale,” continues Luc Brandts, CEO of Software Improvement Group. “Organizations need software portfolio governance that helps developers, AI agents and IT leadership make informed engineering decisions. We believe Sigrid is uniquely positioned to support that need through architecture analysis, benchmarking, and governance capabilities.”

We believe Software Improvement Group's inclusion in the report reflects the increasing demand for solutions that combine software quality measurement, architecture observability, benchmarking, and actionable remediation guidance within modern software engineering Environments.

Download the Gartner report at https://www.softwareimprovementgroup.com/gartner-mq-download/

About Gartner and the Magic Quadrant

Gartner delivers actionable, objective insight to executives and their teams. Its expert guidance and tools enable faster, smarter decisions and stronger performance on an organization's mission-critical priorities. The Gartner Magic Quadrant evaluates vendors based on their Ability to Execute and Completeness of Vision. Software Improvement Group has been recognized in the Gartner® Magic Quadrant™ for Technical Debt Management Tools.

Egiazarov and Howard Dodd, May 2026.

Disclaimer: Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose. Gartner and Magic Quadrant are trademarks of Gartner, Inc., and/or its affiliates.

About Software Improvement Group

Software Improvement Group (SIG) empowers organizations to govern the software their business runs on. Through complete portfolio analysis and tailored strategic advice, SIG helps companies embrace AI with control, improve software quality and security by focusing strategic efforts across people, process, and technology.

For more information, please visit Software Improvement Group's website or social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526960241/en/

Contacts

UK Media contact: softwareimprovementgroup@sourcecodecomms.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom